ORIGINAL ARTICLE

Prognostic value of pre-operative peripheral inflammation markers in patients with squamous cell carcinoma of the external auditory canal

Feitian Li a,b, Xunbei Shi a,b, Chunfu Dai a,b,∗

a Fudan University, Eye, Ear, Nose and Throat Hospital, Department of Otology and Skull Base Surgery, Shanghai, People’s Republic of China  
b Key Laboratory of Hearing Medicine, Ministry of Health, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, People’s Republic of China

Received 16 March 2020; accepted 15 May 2020  
Available online 24 June 2020

KEYWORDS
Ear;  
Cancer;  
Lymphocyte;  
Neutrophil;  
Prognostic factors

Abstract

Introduction: Squamous cell carcinoma of the external auditory canal is a rare entity. Previous studies have suggested predictors for tumor recurrence. However, most of the prognostic factors were from the clinicopathological aspect.

Objective: This study aims to analyze the correlation between pre-operative peripheral inflammation markers and survival outcomes, in order to identify prognostic biomarkers for patients with squamous cell carcinoma of the external auditory canal.

Methods: We retrospectively analyzed patients diagnosed with squamous cell carcinoma of the external auditory canal who underwent surgery at our institute. The pre-operative circulating inflammatory markers, such as the neutrophil, lymphocyte, platelet, and monocyte counts were measured and their ratios including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio were calculated. The prognostic value of the measured hematologic parameters in relation to the survival outcomes was also evaluated.

Results: A total of 83 patients were included, of which 26 patients showed tumor recurrence and 57 without recurrence. Neutrophil counts and neutrophil-to-lymphocyte ratio were closely connected with tumor stage. In the patients with recurrence, neutrophil counts, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio were elevated (p < 0.0001, p < 0.0001 and p=0.001), while lymphocyte counts and lymphocyte-to-monocyte ratio were decreased (p=0.013 and p=0.016, respectively). The receiver operating curve analysis indicated that pre-operative neutrophil-to-lymphocyte ratio is a potential prognostic marker for recurrence.

∗ Corresponding author.  
E-mail: cfdai66@126.com (C. Dai).  
Peer Review under the responsibility of Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.

https://doi.org/10.1016/j.bjorl.2020.05.018  
1808-8694/© 2020 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
of squamous cell carcinoma of the external auditory canal (area under curve = 0.816), and the cut-off points was 2.325.

Conclusions: Pre-operative neutrophil and lymphocyte counts, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte are significantly correlated with tumor recurrence in patients with external auditory canal squamous cell carcinoma. Furthermore, neutrophil-to-lymphocyte ratio may be unfavorable prognostic factors of this disease. © 2020 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction

Squamous cell carcinoma (SCC) of the external auditory canal is a rare malignancy. Thus, limited data are available for this cancer. The current treatment strategy for external auditory canal SCC is either surgery, radiotherapy, chemotherapy, or a combination of these. At the moment, there is no staging system approved by the Union for International Cancer Control or by the American Joint Committee on Cancer for this type of malignancy. The Pittsburgh staging system, which was first proposed in 1996 and modified in 2000, is commonly used in clinical practice to select the surgical approach and to evaluate the survival outcome. Most studies on external auditory canal SCC only analyzed well-established prognostic factors, including the tumor stage, involved structures, and combined adjuvant therapy. However, by only focusing on local invasion, other information, such as tumor immunology and cellular biology may be overlooked. Therefore, new prognostic factors need to be identified.

Since Virchow first described the presence of leukocytes in neoplastic tissues and the correlation of inflammation with cancer in 1863, numerous studies have attempted to elucidate the connection between inflammation and malignancy progression. In recent years, mounting evidence has suggested that counts of different cell types in the circulating blood are associated with survival rates in various malignancies, including gastric cancer, oral carcinoma and nasopharyngeal carcinoma. Additionally, the hematologic ratios, such as the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR), were found to predict the prognosis of patients affected by various cancers. The role of inflammatory cells in the cancer micro-environment and metastasis is also emerging in laboratory research. Lartigue et al. found that circulating tumor cells could be trapped within neutrophil-derived DNA webs after systemic infection, implicating that neutrophils are involved in tumor metastasis. Labelle et al. demonstrated that, after release of TGF-β and direct contact with tumor cells, platelets can activate tumor TGFβ/Smad and NF-κB pathways, enhancing tumor transition toward a more invasive phenotype and metastasis. Reichert et al. showed that the tumor-mediated death of circulating T-cells through the Fas/FasL pathway suppressed the immune anti-tumoral function in oral carcinoma. These findings provide an in-depth understanding of the involvement of inflammatory markers in carcinogenesis, which could provide an evidence base for development of new strategies to manage cancer patients. However, to our knowledge, the prognostic value of pre-operative inflammatory markers in external auditory canal SCC has not yet been tested.

Therefore, in this study, we evaluated the correlation between pre-operative inflammatory markers and prognosis in patients affected with external auditory canal SCC in order to identify new independent prognostic factors for this rare disorder.

Methods

Study population

This study was approved by the medical ethics committee of the Eye, Ear, Nose and Throat Hospital of Fudan University (20140007), and all patients signed informed consent forms.

We performed a retrospective review of all patients diagnosed with external auditory canal SCC who underwent surgery at our institution between January 2005 and December 2018. The inclusion criteria were the following: 1) Primary external auditory canal SCC diagnosis confirmed by a histopathological examination at our institution; 2) Curative temporal bone resection with parotidectomy was performed; 3) Consent for enrollment in the study; 4) Comprehensive medical records, including imaging, laboratory test, and follow-up were available. The following patients were excluded: 1) Patients who underwent pre-operative radiotherapy or chemotherapy; 2) Patients who had a concurrent hematologic disease, systemic inflammatory disease, or infection; 3) Patients who were diagnosed with auto-immune disease or were treated with immune-suppressive agents; 4) Patients who were affected with a suspected distant metastasis after computed tomography and magnetic resonance imaging. Ninety-eight patients met the inclusion criteria, of which 15 patients were later excluded from the survival analysis due to a loss to follow-up.

Data collection

We collected medical records for all the patients involved in the study including laboratory tests results, and radiological and histological findings. Patients were staged according to the Pittsburgh staging system. The patients’ blood samples were collected in ethylenediaminetetraacetic acid-containing tubes within 2 weeks before the opera-
tion. Pre-operative neutrophil, monocyte, lymphocyte, and platelet counts were measured using the Mindary BC-5500 (Shenzhen, China) automatic blood counting system. The NLR, PLR, and LMR were calculated by dividing the absolute values of the corresponding cell counts.

Patient follow-up

All patients were followed up with interval MRI and chest computed tomography after surgery to detect local recurrence or distant metastasis. The last follow-up for all patients was in October 2019. The follow-up duration ranged from 8 to 138 months with a median of 27 months.

Statistical analysis

The Mann-Whitney U test and Kruskal Wallis test were used to compare the mean pre-operative hematologic parameters and calculated ratios stratified by demographics and clinical characteristics. Mann-Whitney U test was applied to compare the pre-operative hematologic parameters and calculated ratios between recures and non-recure patients. Data are presented as mean ± SD. The Receiver-Operating Curve (ROC) analysis was performed to acquire the Youden index (sensitivity + specificity-1), and the optimal cut-off points of neutrophil, monocyte, lymphocyte, platelet counts and NLR, PLR, LMR were calculated. Results were considered significant if two-sided was p < 0.05. All statistical analyses were conducted using the IBM SPSS 20.0 software (IBM, Armonk, NY, USA).

Results

Demographics and clinical characteristics

The patients’ demographics and clinical characteristics are shown in Table 1. The patient cohort was composed of 59 males and 24 females (male: female ratio = 2.46:1) with a mean age of 60.78 ± 9.24 years (range, 35–79 years). The median follow-up time was 27 months (range, 8–138 months). According to the Pittsburgh staging system, 24 patients (28.9%) were at an early stage (T1–T2), whereas 59 patients (71.1%) were at an advanced stage (T3–T4). Furthermore, 4 patients (4.8%) had lymph node metastasis. In 42 patients (50.6%), the tumors were well or moderately differentiated, in 7 (8.4%), they were poorly differentiated, and in 34 patients (41.0%), this was unknown.

Table 1 Patients characteristics.

| Clinical characteristics | Numbers |
|--------------------------|---------|
| Age (< 60 years/ ≥ 60 years) | 33 (39.8%)/50 (60.2%) |
| Sex (male/female) | 59 (71.1%)/24 (28.9%) |
| Stage | |
| T1 | 3 (3.6%) |
| T2 | 21 (25.3%) |
| T3 | 22 (26.5%) |
| T4 | 37 (44.6%) |
| Lymph node status | |
| N0 | 79 (95.2%) |
| N1 | 4 (4.8%) |
| Differentiation patterns | |
| Well & moderately differentiated | 42 (50.6%) |
| Poorly differentiated | 7 (8.4%) |
| Unknown | 34 (41.0%) |

Comparison of hematologic parameters with demographic and clinicopathological characteristics

Comparison of hematological and clinicopathological parameters are shown in Tables 2 and 3. Since lymph node metastasis only occurred in 4 patients, we did not further analyze the correlation between lymph node metastasis and hematologic parameters, as no significant correlation could be drawn in this cohort.

We found no significant differences between the hematologic parameters and demographic characteristics, such as age and sex. However, we found that neutrophil counts and NLR are significantly associated with the tumor stage. Patients with advanced stage cancer (T3–4) had higher neutrophil counts and NLR than those in the early stage (T1–2). In addition we found no significant correlation between the differentiation patterns and any hematologic parameters.

Correlation of hematologic parameters with follow-up outcomes

During follow-up, we observed 26 recurrences. Of the patients showing recurrence, 18 eventually died of EACSCC, while 8 were alive with local recurrence at their last follow-up. Fifty-seven patients showed no recurrence, among them 55 patients were alive without evidence of disease, while two died of cardiac disease and colon cancer, respectively. None of the 83 patients developed distant metastasis.

The mean pre-operative neutrophil, monocyte, lymphocyte and platelet counts was 4.56 ± 1.47, 0.46 ± 0.15, 1.44 ± 0.57 and 212.50 ± 62.10 in recur patients, and 3.40 ± 0.91, 0.43 ± 0.16, 1.79 ± 0.60, 194.0 ± 55.18 in non-recure patients, respectively. The mean pre-operative NLR,
Table 2  Means of pre-operative hematologic parameters ($\times 10^6$), stratified by demographic and clinicopathological characteristics.

| Variables         | Neu (Mean ± SD) | $p$ | Mon (Mean ± SD) | $p$ | Lym (Mean ± SD) | $p$ | Plt (Mean ± SD) | $p$ |
|-------------------|----------------|-----|----------------|-----|----------------|-----|----------------|-----|
| Age               |                |     |                |     |                |     |                |     |
| <60 years         | 3.91 ± 1.02    | 0.105 | 0.47 ± 0.16    | 0.180 | 1.72 ± 0.69    | 0.186 | 209.20 ± 51.68 | 0.058 |
| ≥ 60 years        | 3.66 ± 1.35    |     | 0.42 ± 0.16    |     | 1.57 ± 0.60    |     | 193.60 ± 61.05 |     |
| Sex               |                | 0.077 |                | 0.074 | 1.64 ± 0.63    | 0.599 |                | 0.357 |
| M                 | 3.34 ± 0.82    |     | 0.39 ± 0.11    |     | 1.70 ± 0.61    |     | 205.10 ± 50.54 |     |
| F                 | 3.93 ± 1.33    |     | 0.46 ± 0.17    |     | 1.70 ± 0.61    |     | 197.30 ± 60.60 |     |
| Stage             |                | 0.018 |                | 0.226 | 1.73 ± 0.68    | 0.597 |                | 0.981 |
| T1–T2             | 3.26 ± 0.81    |     | 0.40 ± 0.13    |     | 1.80 ± 0.78    |     | 196.40 ± 50.21 |     |
| T3                | 3.66 ± 1.23    |     | 0.45 ± 0.20    |     | 1.58 ± 0.42    |     | 200.60 ± 59.72 |     |
| T4                | 4.15 ± 1.34    |     | 0.46 ± 0.14    |     | 1.74 ± 0.65    |     | 208.20 ± 54.49 |     |
| Differentiation   |                | 0.074 |                | 0.981 | 2.85 ± 0.23    | 0.291 |                | 0.770 |
| pattern           |                |     |                |     | 1.54 ± 0.71    |     | 200.00 ± 74.78 |     |
| Well & moderate   | 4.33 ± 1.49    |     | 0.47 ± 0.15    |     | 1.74 ± 0.65    |     | 208.20 ± 54.49 |     |
| Poor              | 3.54 ± 1.37    |     | 0.48 ± 0.23    |     | 1.54 ± 0.71    |     | 200.00 ± 74.78 |     |

Neu, neutrophils; Mon, monocytes; Lym, lymphocytes; Plt, platelets.

Table 3  Means of pre-operative NLR, PLR, and LMR, stratified by demographic and clinicopathological characteristics.

| Variables         | NLR (Mean ± SD) | $p$ | PLR (Mean ± SD) | $p$ | LMR (Mean ± SD) | $p$ |
|-------------------|----------------|-----|----------------|-----|----------------|-----|
| Age               |                |     |                |     |                |     |
| < 60 years        | 2.50 ± 1.50    | 0.474 | 130.20 ± 59.88 | 0.647 | 4.22 ± 1.74    | 0.665 |
| ≥ 60 years        | 2.59 ± 1.64    |     | 134.40 ± 68.38 |     | 4.17 ± 1.92    |     |
| Sex               |                | 0.400 |                | 0.216 |                | 0.132 |
| M                 | 2.30 ± 1.24    |     | 137.60 ± 51.71 |     | 4.61 ± 1.92    |     |
| F                 | 2.66 ± 1.69    |     | 130.70 ± 69.72 |     | 4.02 ± 1.80    |     |
| Stage             |                | 0.009 |                | 0.665 |                | 0.212 |
| T1–T2             | 2.04 ± 0.61    |     | 124.60 ± 38.05 |     | 4.56 ± 1.84    |     |
| T3                | 2.62 ± 2.33    |     | 130.60 ± 73.00 |     | 4.42 ± 2.10    |     |
| T4                | 2.85 ± 1.41    |     | 139.20 ± 73.74 |     | 3.82 ± 1.65    |     |
| Differentiation   |                | 0.542 |                | 0.962 |                | 0.218 |
| pattern           |                |     |                |     | 140.00 ± 76.67 |     |
| Well & moderate   | 2.90 ± 1.80    |     | 173.90 ± 155.20|     | 4.01 ± 1.65    |     |
| Poor              | 2.67 ± 1.30    |     | 173.90 ± 155.20|     | 3.26 ± 1.20    |     |

M, male; F, female; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

Figure 2  Comparison of NLR (A), PLR (B) and LMR (C) in recur and non-recur patients. NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

PLR, LMR was 3.76 ± 2.70, 174.20 ± 93.92, 3.50 ± 1.69 in recur patients and 2.00 ± 0.55, 113.80 ± 32.31, 4.50 ± 1.84 in non-recur patients, respectively. Mann-Whitney test revealed that neutrophil counts, NLR and PLR significantly increased in recur patients ($p < 0.0001$, $p < 0.0001$ and $p = 0.001$, respectively), while lymphocyte counts and LMR decreased in recur patients ($p = 0.013$ and $p = 0.016$, respectively) (Figs. 1 and 2).
This prognostic ability of hematological parameters and ratios for patients with external auditory canal SCC were analyzed by the ROC analyses. The results are shown in Fig. 3. The Area Under Curve (AUC) of neutrophil, lymphocyte, platelet and monocyte counts was 0.761, 0.670, 0.618 and 0.552, with the 95% Confidence Interval varying from 0.657 to 0.866, 0.539–0.801, 0.495–0.741 and 0.422–0.482, and \( p < 0.001, <0.05, <0.05 \) and \(<0.05\), respectively. The AUC of NLR, PLR and LMR was 0.815, 0.721, 0.665, with the 95% Confidence Interval varying from 0.707 to 0.924, 0.593–0.848, 0.528–0.803, and \( p < 0.0001, <0.01, <0.05\), respectively. The cut-off points were calculated between recur and non-recur patients. The optimal cut-off points were \( 3.75 \times 10^9 / L \) for neutrophil counts, \( 1.77 \times 10^9 / L \) for lymphocyte counts, \( 2.325 \) for NLR, \( 157.9 \) for PLR and \( 3.065 \) for LMR.

Our study revealed that in patients with external auditory canal SCC, pre-operative neutrophil and lymphocyte counts, NLR, PLR and LMR were associated with tumor recurrence. NLR may be unfavorable prognostic factors for survival outcome of EACSCC patients.

**Discussion**

This study evaluated the prognostic value of comprehensive pre-operative inflammatory hematologic parameters (neutrophil, platelet, lymphocyte, and monocyte counts) and calculated ratios (NLR, PLR and LMR) for patients with external auditory canal SCC. Our results show that pre-operatively elevated neutrophil counts, NLR, PLR and decreased lymphocyte counts, LMR were significantly correlated with recurrence of EACSCC. In terms of tumor progression, our results showed that neutrophil counts and NLR were correlated with tumor stage. Although the prognostic value of pre-operative hematologic parameters had already been validated for various tumors, including head and neck cancers, our study was the first to evaluate their prognostic value for external auditory canal SCC patients.

Previous studies have reported that males have higher neutrophil, lymphocyte, and platelet counts than females. However, in this study we observed no statistical difference in the blood cells counts and ratios between the sexes and ages. Our study showed that an increase in neutrophil counts and NLR are correlated with the tumor stage. Neutrophils are bone marrow-derived myeloid cells that can be recruited to tumors, where they promote tumor progression by facilitating angiogenesis, inhibiting T-cell activity, and participating in other biological events. This may explain the correlation between tumor stage and neutrophil counts, and NLR.

What is more, neutrophils have an established dual role in the host’s defense toward infection and secreting cytokines and enzymes that stimulate tumor growth, promoting tumor angiogenesis and metastasis. Additionally, neutrophils can behave as immunosuppressive cells by inhibiting T-cell activity through the production of nitrogen and reactive oxygen species. This observation can explain why NLR is a useful prognostic factor for cancer patients. Balempas et al. reported that a favorable survival rate in patients with head and neck cancer was associated with higher pre-treatment levels of infiltrating CD3+ and CD8+ lymphocytes. Zhang
et al. showed that the absence of intra-tumoral T-cells in ovarian carcinoma is associated with an increased expression of the Vascular Endothelial Growth Factor (VEGF), which promotes tumor angiogenesis. The presence of intra-tumoral T-cells is correlated with a late recurrence and an improved survival rate. Platelets can stimulate tumor metastasis by promoting cell aggregation to shield tumor cells from immune surveillance. Increased platelet levels can stimulate osteoclast activity and facilitate bone metastasis. Circulating monocytes are recruited to the tumor site, where they differentiate into Tumor-Associated Macrophages (TAMs) by tumor-produced chemokines. TAMs produce a variety of molecules that promotes tumor angiogenesis and stimulates tumor cell growth, such as VEGF, IL-1, hypoxia-inducible factor-2α, fibroblast growth factor and hepatocyte growth factor. TAMs also contribute to tumor metastasis by producing basement membrane proteases. In summary, extensive studies have demonstrated interactions between peripheral hematologic parameters and tumors.

Previous studies reported that NLR significantly predicts a worse outcome in various cancers. And high neutrophil and monocyte circulating levels, and low circulating lymphocyte levels were correlated with poor prognosis. Furthermore, Rachidi et al. independently confirmed that a lower platelet count predicted a better prognosis, and that administration of anti-platelet agents improved survival of patients with head and neck SCC. Xie et al. showed that pre-operative PLR inversely correlated with Cancer Specific Survival (CSS) in patients with esophageal SCC. Several studies have reported that the LMR is associated with prognosis in cancer patients. These results validate the use of peripheral inflammation markers to predict postoperative outcomes in cancer patients. In this study, we found the pre-operative neutrophil counts, NLR, PLR were higher, while lymphocyte counts and LMR were lower in patients with recurrence compared to the non-recurrence patients. As shown in Fig. 3, the cut-off points were 3.75 × 10^9/L for neutrophil counts, 1.77 × 10^9/L for lymphocyte counts, 2.325 for NLR, 157.9 for PLR and 3.065 for LMR in our study. NLR can serve as a potential prognostic marker in clinical practice with an ideal AUC value of 0.816.

However, this study had some limitations, including its retrospective design and the relatively small sample size, which may lead to referral biases. Therefore, further studies are necessary to validate the role and the prognostic utility of systemic inflammatory markers in such patients.

Conclusions

Taken together, our results suggested that pre-operative neutrophil and lymphocyte counts, NLR, PLR, and LMR are significantly in relation to EACSCC recurrence. Furthermore, NLR may serve as potential prognostic markers to predict worse outcomes in patients with external auditory canal SCC.

Funding

This study was funded by the National Natural Science Foundation of China (no 81771009).

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Arriaga M, Curtin H, Takahashi H, Hirsch BE, Kamerer DB. Staging proposal for external auditory meatus carcinoma based on preoperative clinical examination and computed tomography findings. Ann Otol Rhinol Laryngol. 1990;99:714–21.
2. Moody SA, Hirsch BE, Myers EN. Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol. 2000;21:582–8.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
4. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
6. Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446–58.
7. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90.
8. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8:3137–45.
9. Rachidi S, Wallace K, Wrangle C, Day TA, Alberg AJ, Li Z. Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. Head Neck. 2016;38 Suppl 1:E1068–74.
10. Hsueh C, Tao L, Zhang M, Cao W, Gong H, Zhou J, et al. The prognostic value of preoperative neutrophils, platelets, lymphocytes, monocytes and calculated ratios in patients with laryngeal squamous cell carcinoma. Oncotarget. 2017;8:60514–27.
11. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618–31.
12. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010;70:5767–85.
13. Tecchio C, Scapini P, Pizzolo G, Cassatella MA. On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol. 2013;23:159–70.
14. Müller I, Munder M, Kropf P, Hänisch GM. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol. 2009;30:522–30.
15. Balkemps P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110:501–9.
16. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.
17. Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2014;229:1005–15.
18. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.
19. Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG. Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg. 2016;263:292–7.
20. Tu XP, Qiu QH, Chen LS, Luo XN, Lu ZM, Zhang SY, et al. Preoperative neutrophil-to-lymphocyte ratio is an independent prognostic marker in patients with laryngeal squamous cell carcinoma. BMC Cancer. 2015;15:743.
21. Huang SH, Waldron JN, Milosevic M, Shen X, Ringash J, Su J, et al. Prognostic value of pretreatment circulating neutrophils, monocytes and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015;121:545–55.
22. Valero C, Pardo L, López M, García J, Camacho M, Quer M, et al. Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer. Head Neck. 2017;39:219–26.
23. Rachidi S, Wallace K, Day TA, Alberg AJ, Li Z. Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. J Hematol Oncol. 2014;7:65.
24. Xie X, Luo KJ, Hu Y, Wang JY, Chen J. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. Dis Esophagus. 2016;29:79–85.